Clinical trials
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia clinical trials
Below are recruiting relapsed or refractory b-cell acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 1,801 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
New Haven, ConnecticutAges 18 years+ - NCT07387926RecruitingPhase 1/Phase 2
Testing asciminib for children and young adults with a type of leukemia
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Ramat GanAges 1–30 - NCT07121946RecruitingPhase 1
Safety study of LTZ-301 for non-Hodgkin lymphoma
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Duarte, CaliforniaAges 18 years+ - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Baltimore, MarylandAges 12 years+ - NCT03826992RecruitingPhase 1
Study drug Venetoclax plus Vyxeos for hard-to-treat leukemia
This Phase 1 study tests whether a combination of venetoclax and Vyxeos can treat children and young adults with certain relapsed or treatment-resistant acute leukemias. It may help shrink the leukemia or improve blood counts when standard treatments have not worked.
Cincinnati, OhioAges 1–39 - NCT05305859RecruitingPhase 2
Venetoclax, chidamide, and azacitidine for hard-to-treat AML
This Phase 2 trial tests whether adding three medicines—venetoclax, chidamide, and azacitidine—can help adults whose AML has come back or did not respond to treatment. It may help shrink or control the leukemia and improve outcomes for people who fit the study’s health and lab requirements.
Xiamen, FujianAges 18 years+ - NCT05512169Recruiting
Genetic study in Indian children with newly diagnosed leukemia
This study looks at genetic (DNA) differences to understand acute lymphoblastic leukemia (ALL) in Indian children and how treatments may fit better. You may be able to join if your child is newly diagnosed, meets the study’s treatment plan rules, and provides consent.
New DelhiAges 1–18 - NCT05858814RecruitingPhase 1/Phase 2
Cell therapy to help prevent AML relapse after transplant
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
Hefei, AnhuiAges 18–70 - NCT06022003RecruitingPhase 2
Azacitidine plus gilteritinib for FLT3-mutated AML
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
AmiensAges 18 years+ - NCT06104592RecruitingPhase 2
Radiation before CAR T-cell therapy for high-risk large B-cell lymphoma
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Tampa, FloridaAges 18 years+ - NCT06299540Recruiting
Physical activity program for CLL patients on ibrutinib
This study tests whether a personalized physical activity program can improve quality of life for people with CLL who are starting the drug ibrutinib. You would wear an activity watch and use a digital tool to track your activity over time.
ToulouseAges 18 years+ - NCT06316960RecruitingPhase 2
Avapritinib for children with relapsed or resistant CBF-AML and KIT mutation
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
Hefei, AnhuiAges Up to 18 years - NCT06428188RecruitingPhase 1/Phase 2
CAR-T cells targeting BCMA/CD19 for autoimmune diseases
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT06462248RecruitingPhase 2
CAR-T therapy for B-cell blood cancers
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on B-cell cancer cells. It is for children and adults with B-cell acute lymphoblastic leukemia or certain B-cell lymphomas that have not improved with standard treatments.
Hong KongAges 1 year+ - NCT06481735RecruitingPhase 1/Phase 2
Modified donor CAR-T for B-cell leukemia
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
Beijing, Beijing MunicipalityAges 16–70 - NCT07008885RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed/refractory B-ALL
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Beijing, Biotherapeutic Department of Chinese PLA General HospitalAges 18–70 - NCT07131254RecruitingEarly Phase 1
Study of GT719 cell therapy for CD19-positive leukemia or lymphoma
This study is testing a new cell therapy called GT719 for people with B-cell leukemia or lymphoma that has not responded to standard treatments. The therapy targets a protein called CD19 on cancer cells, aiming to kill them.
Ganzhou, JiangxiAges 18–75 - NCT05690191Enrolling by invitation
Chidamide treatment for returning or hard-to-treat lymphoma
This trial studies chidamide (a prescription medicine) in people with diffuse large B-cell lymphoma that has come back or did not respond to at least one prior treatment. It may help shrink tumors and improve disease control for eligible patients.
Suzhou, JiangsuAges 18 years+ - NCT06839053RecruitingPhase 2
Study of sonrotoclax, rituximab, and zanubrutinib for CLL, SLL, and MCL
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
Seattle, WashingtonAges 18 years+ - NCT07211737RecruitingPhase 1
C7R-GD2 CAR-T cells for osteosarcoma or neuroblastoma
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
Houston, TexasAges 1–24 - NCT06564038RecruitingPhase 1/Phase 2
Study of AZD0486 alone or with other drugs for B-cell cancers
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
Boston, MassachusettsAges 18 years+ - NCT05365659RecruitingPhase 1
Testing IKS03 for advanced B-cell lymphoma
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
Baltimore, MarylandAges 18 years+ - NCT06526793RecruitingPhase 2
Surovatamig for relapsed or refractory B-cell lymphoma
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Phoenix, ArizonaAges 18 years+ - NCT07197307RecruitingPhase 2
Study of two targeted drugs for relapsed aggressive B-cell lymphoma
This study tests a new combination of two drugs—loncastuximab tesirine (an antibody-drug conjugate) and epcoritamab (a bispecific antibody)—for people whose aggressive B-cell lymphoma has returned or not responded to prior treatment. The goal is to see if the combination is safe and effective.
AachenAges 18 years+
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 1,801 recruiting relapsed or refractory b-cell acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.